Aptose Biosciences (APTOF) CEO exits equity in Hammi Pharmaceuticals buyout
Rhea-AI Filing Summary
Aptose Biosciences Inc.’s Chair, President & CEO William G. Rice disposed of his equity holdings in connection with the company’s acquisition by Hammi Pharmaceuticals. He transferred 613,252 Common Shares at $1.72 per share, reflecting a Canadian price of C$2.41 converted at C$1.4 = US$1.00.
Rice also disposed of multiple stock option and warrant positions to the issuer on the same date, including large employee option grants and performance stock options with exercise prices ranging from $0.25 to $6.91 per share. Following these transactions, the filing shows zero shares and zero listed derivative awards remaining in his direct ownership, consistent with all outstanding shares of Aptose being acquired under a board, shareholder and court‑approved business arrangement with Hammi.
Positive
- None.
Negative
- None.
Insights
CEO’s equity is cashed out in a court‑approved Hammi acquisition, not through open‑market selling.
The filing shows William G. Rice, Aptose’s Chair, President & CEO, disposing of 613,252 Common Shares at $1.72 per share, tied to a Canadian price of C$2.41. Footnotes state this occurred under a board, shareholder and court‑approved business arrangement where a Hammi Pharmaceuticals subsidiary acquired all outstanding Aptose shares.
Rice’s numerous stock options, performance options and warrants, with exercise prices from $0.25 to $6.91, were also disposed of to the issuer, leaving no reported remaining derivative positions. Because these are mandatory deal‑closing mechanics rather than discretionary trades, they mainly confirm completion terms of the Hammi transaction rather than signaling a change in management’s view of the business.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option ("Right to Buy") | 70,000 | $0.00 | -- |
| Disposition | Warrants | 50,000 | $0.00 | -- |
| Disposition | Employee Stock Option ("Right to Buy") | 400,000 | $0.00 | -- |
| Disposition | Performance Stock Options | 600,000 | $0.00 | -- |
| Disposition | Employee Option Grant | 700,000 | $0.00 | -- |
| Disposition | Employee Stock Option ("Right to Buy") | 343,000 | $0.00 | -- |
| Disposition | Employee Option Grant | 2,000,000 | $0.00 | -- |
| Disposition | Stock Options (Right to Buy) | 400,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 300,000 | $0.00 | -- |
| Disposition | Common Shares | 400,000 | $0.00 | -- |
| Disposition | Common Shares | 613,252 | $1.72 | $1.05M |
Footnotes (1)
- Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
Key Figures
Key Terms
Disposition to issuer financial
Employee Stock Option (Right to Buy) financial
Performance Stock Options financial
business arrangement agreement financial
court-approved regulatory
